Gastric Cancer PDX Models
With many new agents under development, including targeted therapies for gastric cancer, there is a need for predictive research models such as patient-derived xenografts (PDX) for preclinical evaluation. PDX models are proven to be highly predictive models for preclinical drug assessment. The Crown Bioscience collection contains over 100 well characterized gastric cancer PDX models, including EGFR amplified models and cachexic models. More
PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
